Symtomax Portugal has been granted approval to commence cultivation from the Portuguese regulatory authority for the pharmaceutical industry. The approval allows Symtomax to cultivate, import and export GACP quality dried flower, produced from their facility in Portugal.
"Symtomax was established in 2017 with a commitment to advancing alternative and effective products to improve the health and well-being of people," the Symtomax team explains. "Our team of professionals have decades of combined experience in cannabis cultivation, adhering to strict procedural and environmental protocols to maximise purity, quality and consistency."
Symtomax´s site of 105 hectares of which 95 hectares, has been approved for the cultivation of medical flower. Symtomax have a large selection of sativa dominant, indica dominant, hybrids and CBD strains. The license will allow Symtomax to develop into a vertically integrated cannabis business, cultivating from both our indoor and outdoor facilities, with future plans for R&D, to processing, packaging and distribution of medicinal cannabis oil and other cannabinoid based products.
"We have established strategic partnerships with leading industry companies dedicated to the promotion and development of cannabis for medicinal purposes, in helping to treat a number of different conditions including cancer, arthritis, Alzheimer’s, depression, dementia, anxiety and even in its use for treating eating disorders such as anorexia."